Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2

被引:97
|
作者
Bluman, LG
Rimer, BK
Berry, DA
Borstelmann, N
Iglehart, JD
Regan, K
Schildkraut, J
Winer, EP
机构
[1] Dana Farber Canc Inst, Breast Oncol Ctr, Dept Care Coordinat, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Gillette Ctr Womens Canc, Boston, MA 02115 USA
[3] Duke Univ, Med Ctr, Canc Prevent Detect & Control Res Program, Durham, NC 27706 USA
[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27706 USA
[5] Duke Univ, Inst Stat & Decis Sci, Durham, NC 27706 USA
[6] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1200/JCO.1999.17.3.1040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study examined baseline knowledge, beliefs, and risk perceptions among a group of 200 women with breast and/or ovarian cancer who participated in a trial designed to improve decision making about genetic testing for BRCA1 and BRCA2. Patients and Methods: Women were identified by self-referral, physician referral, and tumor registry extraction and invited to participate in a randomized trial in which testing for BRCA I and BRCA2 was offered free of charge, Subjects completed baseline questionnaires and interviews that assessed knowledge, attitudes, and perceptions of risk of having an alteration in BRCA1 or BRCA2. Results: Sixty percent of women overestimated their chances of having a BRCA1 or BRCA2 mutation compared with estimates from a BRCA 1/BRCA2 risk model. Women who have at least three relatives with breast or ovarian cancer were one third (95% confidence interval, 0.2 to 0.6) as likely to overestimate their risk of having a BRCA1 or BRCA2 mutation compared with women who have two or fewer affected relatives. Knowledge wets limited about BRCA1 and BRCA2 mutations and cancer risk associated with gene mutations, Eighty-four percent of the women indicated a probable or definite interest in testing. Conclusion: A high proportion of the high-risk women in this study had knowledge deficits about BRCA1 and BRCA2 and overestimated their risk of having a mutation, Although some degree of caution should be used in generalizing the results of this study to practice settings, the data provide insight into the challenges clinicians will face in communicating with patients about cancer genetics. (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:1040 / 1046
页数:7
相关论文
共 50 条
  • [1] Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses
    Bluman, LG
    Rimer, BK
    Sterba, KR
    Lancaster, J
    Clark, S
    Borstelmann, N
    Iglehart, JD
    Winer, EP
    [J]. PSYCHO-ONCOLOGY, 2003, 12 (05) : 410 - 427
  • [2] Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer
    Daniels, Molly S.
    Urbauer, Diana L.
    Stanley, Jennifer L.
    Johnson, Kristin G.
    Lu, Karen H.
    [J]. GENETICS IN MEDICINE, 2009, 11 (09) : 624 - 628
  • [3] Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations
    Andrea E. Wahner Hendrickson
    Jamie N. Bakkum-Gamez
    Fergus J. Couch
    Karthik Ghosh
    Judy C. Boughey
    [J]. Annals of Surgical Oncology, 2017, 24 : 3107 - 3109
  • [4] Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations
    Hendrickson, Andrea E. Wahner
    Bakkum-Gamez, Jamie N.
    Couch, Fergus J.
    Ghosh, Karthik
    Boughey, Judy C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (11) : 3107 - 3109
  • [5] Missense Polymorphisms in BRCA1 and BRCA2 and Risk of Breast and Ovarian Cancer
    Dombernowsky, Sarah Louise
    Weischer, Maren
    Freiberg, Jacob Johannes
    Bojesen, Stig Egil
    Tybjaerg-Hansen, Anne
    Nordestgaard, Borge Gronne
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (08) : 2339 - 2342
  • [6] BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer
    Rosenberg, Shoshana M.
    Ruddy, Kathryn J.
    Tamimi, Rulla M.
    Gelber, Shari
    Schapira, Lidia
    Come, Steven
    Borges, Virginia F.
    Larsen, Bryce
    Garber, Judy E.
    Partridge, Ann H.
    [J]. JAMA ONCOLOGY, 2016, 2 (06) : 730 - 736
  • [7] BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
    Welcsh, PL
    King, MC
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (07) : 705 - 713
  • [8] The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
    Metcalfe, KA
    Lynch, HT
    Ghadirian, P
    Tung, N
    Olivotto, IA
    Foulkes, WD
    Warner, E
    Olopade, O
    Eisen, A
    Weber, B
    McLennan, J
    Sun, P
    Narod, SA
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 222 - 226
  • [9] BRCA1 and BRCA2 Genetic Testing in Breast and/or Ovarian Cancer Families in Iran
    Keshavarzi, Fatemeh
    Javadi, Gholam Reza
    Nafissi, Nahid
    Akbari, Mohammad Esmail
    Yassaee, Vahid Reza
    Farzad, Maryam Sharafi
    Zeinali, Sirous
    [J]. YAKHTEH, 2010, 12 (03): : 329 - 340
  • [10] Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations
    Lu Yao
    Jie Sun
    Juan Zhang
    Yingjian He
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Yuntao Xie
    [J]. Breast Cancer Research and Treatment, 2016, 156 : 441 - 445